Plain-English translation of NCT07638683 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a combination of two medications called and daratumumab (Tec-Dara) for people who have just been diagnosed with multiple myeloma and also have a related condition called light chain amyloidosis. Both conditions involve abnormal plasma cells in the bone marrow. Researchers want to see if this medication combination can help more patients stay disease-free for longer and understand how safe it is.
Multiple myeloma combined with light chain amyloidosis is a serious condition that is hard to treat, and current treatments don't work well enough for many patients. This trial exists to see if this new medication combination can improve outcomes and help people live longer without their disease getting worse.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the two medications under your skin on a regular schedule that changes over time—starting with small doses that increase gradually, then ongoing injections weekly, every two weeks, or every four weeks depending on the phase of treatment. You'll continue treatment for up to 24 cycles (about 2 years) unless your disease gets worse or you have serious side effects. You'll have blood tests and disease assessments every month, and you may need to provide bone marrow samples so researchers can see how well the treatment is working.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China